

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/019,693	01/03/2002	Naoyuki Koizumi	2001-1930A	1850
513 75	590 10/07/2003		EXAM	NER
WENDEROTH, LIND & PONACK, L.L.P. 2033 K STREET N. W. SUITE 800 WASHINGTON, DC 20006-1021			PATEL, SUDHAKER B	
			ART UNIT	PAPER NUMBER
			1624	a
	•		DATE MAILED: 10/07/2003	. 7

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 10/019,693

Applicant(s)

Examiner

SUDHAKER PATEL, D.Sc. Tech.

Art Unit

1624

Naoyuki et al



	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address			
	for Reply				
	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE3 MONTH(S) FROM			
		no event, however, may a reply be timely filed after SIX (6) MONTHS from the			
_	date of this communication. Period for reply specified above is less than thirty (30) days, a reply within th	e statutory minimum of thirty (30) days will be considered timely.			
	period for reply is specified above, the maximum statutory period will apply a to reply within the set or extended period for reply will, by statute, cause th	nd will expire SIX (6) MONTHS from the mailing date of this communication. e application to become ABANDONED (35 U.S.C. § 133).			
- Any re	ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).				
Status	patent term adjustment. 300 07 GTT 1.704(0).				
1) 💢	Responsive to communication(s) filed on Sep 29, 2	003			
2a) 💢	This action is FINAL . 2b) ☐ This act	ion is non-final.			
3) 🗆	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.				
Disposi	tion of Claims				
4) 💢	Claim(s) <u>18-26</u>	is/are pending in the application.			
4	a) Of the above, claim(s)	is/are withdrawn from consideration.			
5) 🗆	Claim(s)	is/are allowed.			
6) 💢	Claim(s) <u>18-26</u>	is/are rejected.			
7) 🗌	Claim(s)	is/are objected to.			
8) 🗌	Claims	are subject to restriction and/or election requirement.			
Applica	tion Papers				
9) 🗌	The specification is objected to by the Examiner.				
10)	The drawing(s) filed on is/are	a) \square accepted or b) \square objected to by the Examiner.			
	Applicant may not request that any objection to the d	rawing(s) be held in abeyance. See 37 CFR 1.85(a).			
11)□	The proposed drawing correction filed on	is: a) \square approved b) \square disapproved by the Examiner.			
	If approved, corrected drawings are required in reply t	to this Office action.			
12)	The oath or declaration is objected to by the Exami	ner.			
Priority	under 35 U.S.C. §§ 119 and 120				
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) [☐ All b)☐ Some* c)⊠ None of:				
	1. 💢 Certified copies of the priority documents hav	e been received.			
	2. \square Certified copies of the priority documents hav	e been received in Application No			
	3. Copies of the certified copies of the priority de application from the International Burea				
*S	ee the attached detailed Office action for a list of the				
14)	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. § 119(e).			
a) [The translation of the foreign language provisiona	I application has been received.			
15)□	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. §§ 120 and/or 121.			
Attachm		_			
~	tice of References Cited (PTO-892)	4) X Interview Summary (PTO-413) Paper No(s). 9			
_	tice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)			
3) ∐ Inf	ormation Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Other:			

Interview Summary

Application No. 10/019,693 Applicant(s)

Naoyuki et al

Examiner

SUDHAKER PATEL, D.Sc. Tech.

Art Unit 1624

All participants (applicant, applicant's representative, PTO	personnel):
(1) SUDHAKER PATEL,D.Sc.Tech.	(3)
(2) Mr Jacob	
Date of Interview Oct 3, 2003	
Type: a) ☒ Telephonic b) ☐ Video Conference c) ☐ Personal [copy is given to 1) ☐ applicant	2) applicant's representative]
Exhibit shown or demonstration conducted: d) Yes	· ·
Claim(s) discussed: Claims 18-26	
Identification of prior art discussed: None	
Agreement with respect to the claims f) was reached Substance of Interview including description of the general any other comments:	I. g) was not reached. h) N/A. I nature of what was agreed to if an agreement was reached, or
U.S.C. 112 para second, and homology of H vs -CH2-/-CF communication will be mailed for applicants' revie with the	eir overseas client.
	dments which the examiner agreed would render the claims copy of the amendments that would render the claims allowable is
i) \square It is not necessary for applicant to provide a sepa	arate record of the substance of the interview (if box is checked).
INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MF already been filed, APPLICANT IS GIVEN ONE MONTH FR	MAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST PEP section 713.04). If a reply to the last Office action has OM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE rd of Interview requirements on reverse side or on attached

U. S. Patent and Trademark Office PTO-413 (Rev. 03-98)

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Examiner's signature, if required

Application/Control Number: 10019693 Page 2

Art Unit: 1624

DETAILED ACTION

Applicants' communication paper # 8 dated 9/29/03 is acknowledged.

Applicants have canceled claims 1-17 and presented new claims 18-26. Therefore, the claims in this application are the claims 18-26.

After further review and reconsideration, this application is found not ready for allowance at this stage for the reasons stated bellow.

Rejections withdrawn:

Rejections made under m 35 U.S.C. 112 paragraph second are now withdrawn because applicants have amended the claims now presented.

Rejections made under 35 U.S.C.112 paragraph one are now withdrawn because applicants have deleted the word "prophylaxis" in the claims.

New rejections (see interview summary):

Claim Rejections - 35 U.S.C. § 112

1. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

2. Claim 26 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Application/Control Number: 10019693 Page 3

Art Unit: 1624

Claim 26 does not recite "in need thereof". Claim recites "administered to a human being". This language include any human being. Correction is required.

Claim Rejections - 35 U.S.C. § 103

- 3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 4. Claims 18-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Young et al(U.S.P. 5192785, also cited as Chemical Abstract DN 119:249709).

Young teaches making of sulfamates with a core: 'Phenyl-Phenyl-O-SO2-NH2".

Instant claims differ by not having instant X1 and X2 as H. However, the claim language also recite that one of them is a methyl (CH3) which differs only by a --CH2-which is a homologue.

Thus, it would have been obvious to one having ordinary skill in the art at the time of invention to prepare instant compounds by modifying or replacing as:

- (I). Replacing H of -CH= of a phenyl ring by alkyl or methyl, and also
- (II).Making the Me group attached at any one of the free positions of phenyl group/core as claimed herein, and try out the use/utility as a pharmaceutical by using

Art Unit: 1624

the conventional chemistry knowledge. The motivation stems from the expectation of making compounds having equal or better medicinal agent.

Page 4

Claims 18-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Youg et al (EP 403185), also cited as Chemical Abstract DN 116:20788).

Young teaches making of sulfamates with a core: Phenyl-Phenyl-O-SO2-NH2".

Instant claims differ by not having instant X1 and X2 as H. However, the claim language also recite that one of them is a methyl (CH3) which differs only by a --CH2-which is a homologue.

Claims 18-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Young et al(U.S.P. 5025031, also cited as Chemical Abstract DN 115:255820).

Young teaches making of sulfamates with a core: Phenyl-Phenyl-O-SO2-NH2".

Instant claims differ by not having instant X1 and X2 as H. However, the claim

language also recite that one of them is a methyl (CH3) which differs only by a --CH2which is a homologue.

Note, the Phenyl group can be attached onto second phenyl group in different positions e.g. para-position to -O-SO2-NH2 i.e. 4-position or positions 2,3,5, or 6. This will provide positional isomers of the pthenyl core.

Analogous alkylene variations would be structurally obvious. See, In re Dillon, 919 F. 2d at 1904. See also Deuel, 51 F. 3d at 1558, 34 U.S.P.Q. 2d at 1214 ("Structural relationships may provide the requisite motivation or suggestion to modify

Art Unit: 1624

one compound to obtain another compound(s)"). For example, one compound may suggest its homolog/isomer, because

homolog/isomer often have similar properties, and therefore, chemists of ordinary skill would ordinarily contemplate making them to try to obtain compounds with improved properties, or merely to satisfy their production goals.

Claiming of a new use, new function or unknown property which is inherently present in the prior art does not necessarily make the claim patentable. In re Best, 562 F. 2d 1252, 1254, 195 USPQ 430, 433 (CCPA 1977). See also MPEP 2141.02.

It has been held that a prior art disclosed compounds is sufficient to render a prima facie case of obviousness as species falling within a genus. See In re SUSI, 440 F 2d 442, 169 USPQ 423, 425 (CCPA 1971), followed by Federal Circuit in Merck & co. V. Biocraft Laboratories, 847 F 2d 804, 10 USPQ 2d 1843, 1846 (Fed. Cir.1989). See In re Dillon 16 USPQ 2nd. 1897, 1923 regarding a prima facie case of obviousness of structurally similar compounds disclosed by prior art" regardless to the properties disclosed in the inventor's application.

5. Claim 24 is objected to because of the following informalities: If claim 25 is allowed, this claim will be a duplicate of claim 25. Also, "agent" is not defined, and this will raise additional issues. Appropriate correction is required.

Application/Control Number: 10019693 Page 6

Art Unit: 1624

Conclusion

Allowable Subject Matter

- 6. Claims 18-26 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112, second paragraph, objections made, and other rejections, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims.
- 7. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 1624

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sudhaker Patel, D.Sc. Tech., whose telephone number is (703) 308 4709.

The examiner can normally be reached on Monday thru' Friday from 8:30 AM to 5:00 PM.

If attempts to reach the examiner by the phone are unsuccessful, the examiner's supervisor, Dr. Mukund Shah can be reached at (703) 308 4716 or Sr. Examiner Mr. Richard Raymond at (703)308 4523.

A facsimile center has been established for Group 1600. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier numbers for accessing the facsimile machine are (703) 308-4556 or (703) 305-3592.

Any inquiry of general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308 1235.

BRUCK KIFLE, PH.D. PRIMARY EXAMINER Page 7

October 3, 2003